Bibliographical noteFunding Information:
This work was supported by the Production Assistance for Cellular Therapies (PACT) program from NIH/NHLBI at University of Minnesota Molecular and Cellular Therapeutics Facility, PACT Contract # HHSN268201000008C. This publication was also supported by the NCI grant P01 CA065493. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
BRB receives remuneration as an advisor to Magenta Therapeutics and Blue Rock Therapeutics; Research funding from BlueRock Therapeutics, Rheos Medicines, Equilibre, Carisma, and is a co‐founder of Tmunity Therapeutics. CGB and JEW received research funding from BlueRock Therapeutics. TM, KLH, MLM, JSM, and DHM have disclosed no conflicts of interest. The authors alone are responsible for the content and writing of the article.
- Quality Control
- T-Lymphocytes, Regulatory
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural